Portal de Periódicos da CAPES

Dasatinib therapy for systemic mastocytosis: four cases

2008; Wiley; Volume: 80; Issue: 5 Linguagem: Inglês

10.1111/j.1600-0609.2008.01048.x

1600-0609

Duncan Purtill, Julian Cooney, Raja Sinniah, Ben Carnley, Gavin Cull, Bradley Augustson, Paul Cannell,

Platelet Disorders and Treatments

European Journal of HaematologyVolume 80, Issue 5 p. 456-458 Dasatinib therapy for systemic mastocytosis: four cases Duncan Purtill, Duncan Purtill Department of Haematology, Royal Perth Hospital, PerthSearch for more papers by this authorJulian Cooney, Julian Cooney Department of Anatomical Pathology, Royal Perth Hospital and Pathwest Laboratory Medicine, PerthSearch for more papers by this authorRaja Sinniah, Raja Sinniah Department of Haematology, Royal Perth Hospital and Pathwest Laboratory Medicine, PerthSearch for more papers by this authorBen Carnley, Ben Carnley Department of Haematology, Royal Perth Hospital and Pathwest Laboratory Medicine, PerthSearch for more papers by this authorGavin Cull, Gavin Cull Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands, WA, AustraliaSearch for more papers by this authorBradley Augustson, Bradley Augustson Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands, WA, AustraliaSearch for more papers by this authorPaul Cannell, Paul Cannell Department of Haematology, Royal Perth Hospital and Pathwest Laboratory Medicine, PerthSearch for more papers by this author Duncan Purtill, Duncan Purtill Department of Haematology, Royal Perth Hospital, PerthSearch for more papers by this authorJulian Cooney, Julian Cooney Department of Anatomical Pathology, Royal Perth Hospital and Pathwest Laboratory Medicine, PerthSearch for more papers by this authorRaja Sinniah, Raja Sinniah Department of Haematology, Royal Perth Hospital and Pathwest Laboratory Medicine, PerthSearch for more papers by this authorBen Carnley, Ben Carnley Department of Haematology, Royal Perth Hospital and Pathwest Laboratory Medicine, PerthSearch for more papers by this authorGavin Cull, Gavin Cull Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands, WA, AustraliaSearch for more papers by this authorBradley Augustson, Bradley Augustson Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands, WA, AustraliaSearch for more papers by this authorPaul Cannell, Paul Cannell Department of Haematology, Royal Perth Hospital and Pathwest Laboratory Medicine, PerthSearch for more papers by this author First published: 13 February 2008 https://doi.org/10.1111/j.1600-0609.2008.01048.xCitations: 41 Duncan Purtill, Department of Haematology, Royal Perth Hospital, Perth, WA, Australia. Tel: (+ 61 8) 92241165; Fax: (+ 61 8) 92243449; e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clinical Invest 1993; 92: 1736–44. 2 Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995; 92: 10560–4. 3 Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish network on mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366–72. 4 Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473–81. 5 Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286–91. 6 Tan A, Westerman D, McArthur GA, Lynch K, Waring P, Dobrovic A. Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 2006; 10: 1373. 7 Gotlib J, Cools J, Malone JM III, Schrier SL, Gilliland G, Coutré SE. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879–91. 8 Valent P, Akin C, Sperr WR. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635–41. 9 Valent P, Horny H-P, Escriban L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603–25. Citing Literature Volume80, Issue5May 2008Pages 456-458 ReferencesRelatedInformation